Prospective study · 2001
Incidence of Sexual Dysfunction Associated With Antidepressant Agents: A Prospective Multicenter Study of 1022 Outpatients
Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F (2001). Incidence of Sexual Dysfunction Associated With Antidepressant Agents: A Prospective Multicenter Study of 1022 Outpatients. The Journal of Clinical Psychiatry.
Among 1,022 outpatients with previously normal sexual function, 59.1% developed sexual dysfunction on antidepressants, from 57.7% to 72.7% with SSRIs versus 24.4% with mirtazapine; men were affected more often (62.4%) than women.
Summary
The Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction followed outpatients with previously normal sexual function who were starting antidepressants, between April 1995 and February 2000. The 1,022 patients (610 women, 412 men; mean age 39.8) were interviewed with a questionnaire covering desire, orgasm, ejaculation, erection and overall sexual satisfaction.
Overall, 59.1% (604 of 1,022) developed sexual dysfunction. Rates differed by drug: fluoxetine 57.7%, sertraline 62.9%, fluvoxamine 62.3%, paroxetine 70.7%, citalopram 72.7%, venlafaxine 67.3%, mirtazapine 24.4%, nefazodone 8%, amineptine 6.9% and moclobemide 3.9%. Men had a higher frequency of sexual dysfunction (62.4%) than women (56.9%), although women reported greater severity. About 40% of patients tolerated their sexual dysfunction poorly.
Limitations
The study was open-label and not randomised, so patients receiving different drugs may have differed in other ways. Some drugs had small groups. Nefazodone and amineptine are no longer widely available.
What it means for you
If you developed delayed ejaculation or other sexual changes after starting an SSRI, you are in the majority, not an exception. Because rates differ between medicines, it is worth raising with the person who prescribes yours.